Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | The exciting future of bispecific antibodies

Hermann Einsele • 14 Sep 2019
IMW 2019
Multiple Myeloma AMG 420 Antibodies Pavurutamab

Prof. Hermann Einsele, MD, FRCP of the University of Würzburg, Würzburg, Germany, discusses the exciting future of bispecific antibodies in MM, specifically AMG-420 and AMG-701. This interview took place at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Hermann Einsele

Improving CAR-T in myeloma: dual-targeting approaches and resistance to T-cell exhaustion 1:35
Improving CAR-T in myeloma: dual-targeting approaches and resistance to T-cell exhaustion
Hermann Einsele • 17 Sep 2025
Ongoing trials in CAR T-cell therapy for multiple myeloma: the CARTITUDE trials and aMMbition 3:17
Ongoing trials in CAR T-cell therapy for multiple myeloma: the CARTITUDE trials and aMMbition
Hermann Einsele • 17 Sep 2025
CAR-T in multiple myeloma: optimizing bridging therapy & moving CAR-T into earlier lines of therapy 11:27
CAR-T in multiple myeloma: optimizing bridging therapy & moving CAR-T into earlier lines of therapy
Hermann Einsele • 10 Feb 2025
Novel CAR-T constructs on the horizon for multiple myeloma 1:16
Novel CAR-T constructs on the horizon for multiple myeloma
Hermann Einsele • 10 Feb 2025

Related Videos

The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry 1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3 2:33
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3
Faith Davies • 7 Dec 2025
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL 2:30
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals